镥-177-PSMA-617：未来的展望。
Lutetium-177-PSMA-617: A Vision of the Future.
机构信息
Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
出版信息
Cancer Biol Ther. 2022 Dec 31;23(1):186-190. doi: 10.1080/15384047.2022.2037985.
Abstract
In the last decade, many life-prolonging therapeutic options have emerged for metastatic castration-resistant prostate cancer (mCRPC). The recent VISION trial is the first to demonstrate a survival benefit of Lutetium-177[Lu]Lu-PSMA-617 in post-chemotherapy mCRPC. This journal club reviews the VISION trial in the context of the earlier TheraP trial of [Lu]Lu-PSMA-617 in mCRPC post docetaxel and androgen pathway inhibition, to provide direction for the real-world application of [Lu]Lu-PSMA-617. Treatment in the control groups differed significantly between both trials and may have influenced outcomes: TheraP mandated cabazitaxel whereas VISION's design could not allow it. In both trials, [Lu]Lu-PSMA-617 had a good safety profile, with common adverse events being fatigue, nausea, dry mouth, marrow suppression and diarrhea. Given its efficacy and favorable safety even in heavily pre-treated patients, [Lu]Lu-PSMA-617 provides hope to mCRPC patients and may be applied to earlier disease stages in future investigations.
摘要
在过去十年中，已经出现了许多延长转移性去势抵抗性前列腺癌（mCRPC）患者生存期的治疗选择。最近的 VISION 试验是第一个证明在化疗后 mCRPC 中镥-177[Lu]Lu-PSMA-617 具有生存获益的试验。本期刊俱乐部将在较早的[Lu]Lu-PSMA-617 在 mCRPC 后多西他赛和雄激素通路抑制治疗中的 TheraP 试验背景下对 VISION 试验进行回顾，为[Lu]Lu-PSMA-617 的实际应用提供指导。两项试验的对照组治疗方法存在显著差异，这可能影响了试验结果：TheraP 试验规定使用卡巴他赛，而 VISION 试验的设计不允许使用卡巴他赛。在两项试验中，[Lu]Lu-PSMA-617 的安全性良好，常见的不良反应包括疲劳、恶心、口干、骨髓抑制和腹泻。鉴于其在治疗广泛预处理患者时的疗效和良好的安全性，[Lu]Lu-PSMA-617 为 mCRPC 患者带来了希望，并可能在未来的研究中应用于更早的疾病阶段。
相似文献
1
Lutetium-177-PSMA-617: A Vision of the Future.镥-177-PSMA-617：未来的展望。
Cancer Biol Ther. 2022 Dec 31;23(1):186-190. doi: 10.1080/15384047.2022.2037985.
2
[Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.[吕]Lu-PSMA-617 对比卡巴他赛用于转移性去势抵抗性前列腺癌（TheraP）患者：一项随机、开放标签、2 期试验。
Lancet. 2021 Feb 27;397(10276):797-804. doi: 10.1016/S0140-6736(21)00237-3. Epub 2021 Feb 11.
3
Therapeutic efficacy, prognostic variables and clinical outcome of Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohort.多线治疗后进展性 mCRPC 中 Lu-PSMA-617 PRLT 的治疗效果、预后变量和临床结果：在该队列中，双示踪剂 PET-CT 上高 FDG 摄取与 Gleason 评分相比的预后意义。
Br J Radiol. 2019 Dec;92(1104):20190380. doi: 10.1259/bjr.20190380. Epub 2019 Nov 1.
4
[Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.[镥]-PSMA-617 放射性核素治疗转移性去势抵抗性前列腺癌患者（LuPSMA 试验）：一项单中心、单臂、2 期研究。
Lancet Oncol. 2018 Jun;19(6):825-833. doi: 10.1016/S1470-2045(18)30198-0. Epub 2018 May 8.
5
Clinical Trial Protocol for LuCAB: A Phase I-II Trial Evaluating Cabazitaxel in Combination with [Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer.LuCAB临床试验方案：一项I-II期试验，评估卡巴他赛联合[镥]镥-PSMA-617用于转移性去势抵抗性前列腺癌患者的疗效。
J Nucl Med. 2025 Apr 1;66(4):572-578. doi: 10.2967/jnumed.124.269252.
6
First real-world clinical experience with [Lu]Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer beyond VISION and TheraP criteria.首例超出VISION和TheraP标准的转移性去势抵抗性前列腺癌患者使用[镥]镥-PSMA-I&T的真实世界临床经验。
Eur J Nucl Med Mol Imaging. 2025 May;52(6):2034-2040. doi: 10.1007/s00259-025-07082-9. Epub 2025 Jan 18.
7
[Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.[Lu]Lu-PSMA-617联合恩杂鲁胺治疗转移性去势抵抗性前列腺癌患者（ENZA-p）：一项开放标签、多中心、随机、2期试验。
Lancet Oncol. 2024 May;25(5):563-571. doi: 10.1016/S1470-2045(24)00135-9. Epub 2024 Apr 12.
8
Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial.[镥]镥-PSMA-617与卡巴他赛治疗转移性去势抵抗性前列腺癌（TheraP）患者治疗反应的预后和预测模型验证：一项随机、开放标签、2期试验的事后分析
Eur Urol Oncol. 2025 Feb;8(1):21-28. doi: 10.1016/j.euo.2024.03.009. Epub 2024 Apr 6.
9
Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study.镥-177 前列腺特异性膜抗原活性与卡巴他赛预处理的转移性去势抵抗性前列腺癌患者结局的决定因素：PACAP 研究。
Eur Urol Oncol. 2024 Oct;7(5):1132-1140. doi: 10.1016/j.euo.2024.03.013. Epub 2024 Apr 24.
10
TheraP: a randomized phase 2 trial of Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603).TheraP：一项关于镥-PSMA-617诊疗性治疗与卡巴他赛治疗进展性转移性去势抵抗性前列腺癌的随机2期试验（临床试验方案ANZUP 1603）
BJU Int. 2019 Nov;124 Suppl 1:5-13. doi: 10.1111/bju.14876. Epub 2019 Oct 22.
引用本文的文献
1
Tumor Segmentation on PSMA PET/CT Predicts Survival in Biochemical Recurrence of Prostate Cancer: A Retrospective Study Using [Ga]Ga-PSMA-11 and [F]-PSMA-1007.基于PSMA PET/CT的肿瘤分割可预测前列腺癌生化复发后的生存率：一项使用[镓]镓-PSMA-11和[氟]氟-PSMA-1007的回顾性研究
Cancers (Basel). 2025 Jul 4;17(13):2249. doi: 10.3390/cancers17132249.
2
Adverse effects and underlying mechanism of rare earth elements.稀土元素的不良反应及潜在机制
Environ Health. 2025 May 11;24(1):31. doi: 10.1186/s12940-025-01178-3.
3
Therapeutic Challenges in Metastatic Castration-Resistant Prostate Cancer: A Case Study and Review of Prostate-Specific Membrane Antigen-Targeted Therapy Failures in Highly Prostate-Specific Membrane Antigen-Avid Disease.转移性去势抵抗性前列腺癌的治疗挑战：一项病例研究及对高前列腺特异性膜抗原亲和性疾病中前列腺特异性膜抗原靶向治疗失败的综述
Cureus. 2024 Dec 22;16(12):e76224. doi: 10.7759/cureus.76224. eCollection 2024 Dec.
4
Multicentric Ga-PSMA PET radiomics for treatment response assessment of Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer.多中心Ga-PSMA PET放射组学用于评估转移性去势抵抗性前列腺癌患者接受Lu-PSMA-617放射性配体治疗的疗效
Front Nucl Med. 2023 Sep 14;3:1234853. doi: 10.3389/fnume.2023.1234853. eCollection 2023.
5
Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the Ga- and Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi).定制成纤维细胞激活蛋白靶向治疗：镓和镥标记的单体和二聚体成纤维细胞激活蛋白抑制剂 DOTA.SA.FAPi 和 DOTAGA.(SA.FAPi) 的比较临床前评价。
Molecules. 2024 Jun 28;29(13):3093. doi: 10.3390/molecules29133093.
6
Innovative Drug Modalities for the Treatment of Advanced Prostate Cancer.用于治疗晚期前列腺癌的创新药物模式
Diseases. 2024 May 2;12(5):87. doi: 10.3390/diseases12050087.
7
Preclinical Study of Therapeutic Efficacy of a New Russian Radiopharmaceutical Lu-DOTA-PSMA.新型俄罗斯放射性药物 Lu-DOTA-PSMA 的治疗功效的临床前研究。
Bull Exp Biol Med. 2023 Dec;176(2):224-226. doi: 10.1007/s10517-024-05999-z. Epub 2024 Jan 9.
8
Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu-PSMA-617.中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值、全身免疫炎症指数和泛免疫炎症值在接受 177Lu-PSMA-617 治疗的转移性去势抵抗性前列腺癌患者中的预后作用。
Medicine (Baltimore). 2023 Nov 24;102(47):e35843. doi: 10.1097/MD.0000000000035843.
9
Synthesis and clinical application of new drugs approved by FDA in 2022.2022年美国食品药品监督管理局批准的新药的合成与临床应用
Mol Biomed. 2023 Sep 4;4(1):26. doi: 10.1186/s43556-023-00138-y.
10
Emerging treatment options for prostate cancer.前列腺癌的新兴治疗选择。
Expert Rev Anticancer Ther. 2023 Jun;23(6):625-631. doi: 10.1080/14737140.2023.2208352. Epub 2023 May 2.
本文引用的文献
1
Prostate cancer.前列腺癌。
Lancet. 2021 Sep 18;398(10305):1075-1090. doi: 10.1016/S0140-6736(21)00950-8. Epub 2021 Aug 6.
2
Hematologic safety of Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer.Lu-PSMA-617放射性配体疗法在转移性去势抵抗性前列腺癌患者中的血液学安全性
EJNMMI Res. 2021 Jul 3;11(1):61. doi: 10.1186/s13550-021-00805-7.
3
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.镥 177-PSMA-617 治疗转移性去势抵抗性前列腺癌。
N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23.
4
Evolving role of Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer-a systematic review and meta-analysis.Ac-PSMA 放射性配体治疗在转移性去势抵抗性前列腺癌中的作用演变：系统评价和荟萃分析。
Prostate Cancer Prostatic Dis. 2021 Sep;24(3):880-890. doi: 10.1038/s41391-021-00349-w. Epub 2021 Mar 21.
5
Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.镥-177 标记 PSMA 配体治疗转移性去势抵抗性前列腺癌的疗效和生存的真实世界数据分析。
Target Oncol. 2021 May;16(3):369-380. doi: 10.1007/s11523-021-00801-w. Epub 2021 Mar 9.
6
[Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.[吕]Lu-PSMA-617 对比卡巴他赛用于转移性去势抵抗性前列腺癌（TheraP）患者：一项随机、开放标签、2 期试验。
Lancet. 2021 Feb 27;397(10276):797-804. doi: 10.1016/S0140-6736(21)00237-3. Epub 2021 Feb 11.
7
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.镥-177-PSMA 治疗失败后的晚期转移性去势抵抗性前列腺癌中锕-225-PSMA-617 的活性和不良事件
Eur Urol. 2021 Mar;79(3):343-350. doi: 10.1016/j.eururo.2020.11.013. Epub 2020 Dec 5.
8
Lu-PSMA for advanced prostate cancer: are we ready to play big?用于晚期前列腺癌的镥-前列腺特异性膜抗原：我们准备好大展身手了吗？
Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2325-2328. doi: 10.1007/s00259-020-05102-4.
9
Efficacy and Safety of Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study.Lu 标记前列腺特异性膜抗原放射性核素治疗弥漫性骨髓受累患者的疗效和安全性：一项多中心回顾性研究。
Eur Urol. 2020 Aug;78(2):148-154. doi: 10.1016/j.eururo.2020.05.004. Epub 2020 Jun 10.
10
Real-World Evidence of Clinical Outcomes in Precision Radionuclide Oncology: The NIGHTCAP Study of 177Lu-PSMA in Metastatic Prostate Cancer.真实世界中精准放射性核素肿瘤学临床结局的证据：177Lu-PSMA 在转移性前列腺癌中的 NIGHTCAP 研究。
Curr Pharm Des. 2020;26(31):3799-3803. doi: 10.2174/1381612826666200312141347.
Zotero 插件